Curex vs REMEVi
Two GLP-1 desks, one scoreboard. We put Curex and REMEVi head-to-head on the published Brief Score — the same six factors, scored the same way.
Curex
FDA warning letter, September 2025 — issued to Curex. See the FDA's warning letter database.
REMEVi
The verdict
REMEVi takes this head-to-head.
REMEVi scores 87 to 86 on our six-factor Brief Score — REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
That doesn't make Curex a bad call — it's best for readers who want one predictable price across sema and tirz from an accredited, nationwide desk. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Curex | REMEVi | |
|---|---|---|
| Brief Score | 86/100 (B) | 87/100 (B+) |
| Semaglutide | $199/mo | $219/mo (all doses, compounded) |
| Tirzepatide | $199/mo | $319/mo (all doses, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Curex: Flat $199 on both molecules; LegitScript-certified and nationwide.
REMEVi: New to the tracker on 1 August 2026, and read on the provider's own site rather than taken on trust: we checked https://remevihealth.com/pricing on 2026-08-01 and this row reflects what that page says. The line we publish is $219/mo (all doses, compounded). There is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.